RGNX vs DMAC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DMAC Captures Institutional Edge (3โ1 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while RGNX counters with relative strength in Valuation. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RGNX Revenue | DMAC Revenue | RGNX Op. Margin | DMAC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $220M | $0M | 40.3% | -1352.2% | RGNX |
| FY2019 | $40M | N/A | -422.9% | N/A | RGNX |
| FY2020 | $150M | N/A | -77.1% | N/A | RGNX |
| FY2021 | $470M | N/A | 34.0% | N/A | RGNX |
| FY2022 | $110M | N/A | -233.2% | N/A | RGNX |
| FY2023 | $90M | N/A | -297.1% | N/A | RGNX |
| FY2024 | $80M | N/A | -280.0% | N/A | RGNX |
| FY2025 | $170M | N/A | -94.6% | N/A | RGNX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RGNX | DMAC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $500.9M | $503.1M | Larger Scale | Tie |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -69.2% | +0.0% | Higher Growth | DMAC |
| Operating Margin (TTM) Profitability | -120.4% | 0.0% | Higher Margin | DMAC |
| Net Profit Margin Profitability | -113.9% | 0.0% | Higher Margin | DMAC |
| Return on Equity (ROE) Capital Efficiency | -113.2% | -114.6% | Higher ROE | RGNX |
| 52-Week Range Position Momentum | 19% ($5โ$16) | 55% ($5โ$11) | Stronger Trend | DMAC |
| Beta / 30D Volatility Risk Regime | 1.81ฮฒ ยท 76% Vol | 1.74ฮฒ ยท 98% Vol | Lower Realized Risk | RGNX |
| Unified Institutional Score Composite Signal | 45.3 / 100 (HOLD) | 46.3 / 100 (HOLD) | Higher Composite | DMAC |